Sensus Healthcare (NASDAQ:SRTS) Upgraded to “Buy” by ValuEngine
A number of other analysts have also issued reports on SRTS. Maxim Group restated a buy rating and issued a $11.00 target price on shares of Sensus Healthcare in a report on Friday, May 10th. TheStreet lowered Sensus Healthcare from a c- rating to a d+ rating in a report on Wednesday, May 22nd. HC Wainwright restated a buy rating and issued a $9.00 target price on shares of Sensus Healthcare in a report on Monday, May 13th. Finally, Alliance Global Partners lowered Sensus Healthcare from a buy rating to a neutral rating in a report on Friday, May 10th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $9.50.
SRTS opened at $6.01 on Friday. The firm has a fifty day simple moving average of $5.35. The stock has a market capitalization of $98.09 million, a price-to-earnings ratio of -42.93 and a beta of -0.21. Sensus Healthcare has a 12-month low of $4.75 and a 12-month high of $9.23.
Several large investors have recently made changes to their positions in SRTS. Wells Fargo & Company MN purchased a new stake in shares of Sensus Healthcare during the second quarter worth $30,000. Northern Trust Corp acquired a new position in Sensus Healthcare during the fourth quarter worth $86,000. BerganKDV Wealth Management LLC acquired a new position in Sensus Healthcare during the first quarter worth $88,000. B. Riley Wealth Management Inc. acquired a new position in Sensus Healthcare during the first quarter worth $117,000. Finally, Spark Investment Management LLC acquired a new position in Sensus Healthcare during the first quarter worth $155,000. Institutional investors and hedge funds own 9.53% of the company’s stock.
About Sensus Healthcare
Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
See Also: 12b-1 Fees
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.